| Therapeutic effects of potassium sodium hydrogen citrate on melamine-induced urinary calculi in China 2010 · Group 1 (low dose) · Infants and children with melamine-induced urinary calculi; average age 18.2 months | 1 g | 26 weeks | — |
| Therapeutic effects of potassium sodium hydrogen citrate on melamine-induced urinary calculi in China 2010 · Group 2 (high dose) · Infants and children with melamine-induced urinary calculi; average age 18.2 months | 2 g | 26 weeks | — |
| Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial 2024 · Inorganic nitrate · Adults aged 18 or older with non-ST-elevation acute coronary syndrome at risk of contrast-induced nephropathy, undergoing coronary angiography | 12 mmol | 5 days | 319 |
| Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study 2024 · PCSC · Adults aged 20–80 with mild-stage CKD (stages G2, G3a, or G3b) | 1.5 g | 2 years | 32 |
| Effects of magnesium and potassium supplementation on insomnia and sleep hormones in patients with diabetes mellitus 2024 · T3: Potassium · Men and women aged 19–65 with diabetes and insomnia | 500 mg | 60 days | 74 |
| [Efficacy of thyroxine and potassium iodide treatment of benign nodular thyroid lesions] 2003 · potassium iodide group · Patients with benign nodular thyroid lesions | 200 mcg | 26 weeks | 59 |
| Does a pretreatment with a dentine hypersensitivity mouth-rinse compensate the pain caused by professional mechanical plaque removal? A single-blind randomized controlled clinical trial 2021 · DPOX (test 1) · Adults attending periodontal maintenance or dental prophylaxis for primary or secondary periodontal prevention, with gingivitis or periodontitis | 40 mL | 7 days | 52 |
| An open, parallel group study comparing a frusemide/amiloride diuretic and a diuretic containing cyclopenthiazide with sustained release potassium in the treatment of congestive cardiac failure--a multicentre general practice study 1990 · cyclopenthiazide/potassium · Patients with cardiac failure requiring diuretic treatment | 8.1 mmol | 12 weeks | 35 |
| Short-term effects of combined treatment with potassium bromide and methimazole in patients with Graves' disease 2012 · combined treatment group · patients with Graves' disease | 3 g | 30 days | 30 |
| The effect of increased plasma potassium on myocardial function; a randomized POTCAST substudy 2023 · intervention group · Adults with an implantable cardioverter defibrillator, low-normal to moderately reduced left ventricular ejection fraction (35–55%), and cardiovascular disease; mean age 58 years, 81% male | 2.7 g | 47 days | 25 |
| A pilot study of potassium supplementation in the treatment of hypokalemic patients with rheumatoid arthritis: a randomized, double-blinded, placebo-controlled trial 2008 · potassium group · Adult female patients with active rheumatoid arthritis and hypokalemia; mean age 48.6 years | 6 g | 4 weeks | 16 |
| An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/potassium chloride in the treatment of mild congestive cardiac failure 1990 · bumetanide/potassium chloride · Adults with mild congestive cardiac failure | 573 mg | 8 weeks | 9 |
| Effect of potassium phosphate supplementation on perceptual and physiological responses to maximal graded exercise 2001 · PHOS · Highly trained endurance runners; age and sex not specified | 4 g | 2 days | 8 |
| Effects of sodium and potassium supplementation on endothelial function: a fully controlled dietary intervention study 2015 · supplemental K · Untreated adults with elevated blood pressure or prehypertension; age range and sex not stated | 2.8 g | 4 weeks | — |
| Postprandial Vascular Effects of a High Potassium Meal in Patients with Treated Hypertension 2024 · High-potassium meal · Adults aged 18–80 with controlled, treated hypertension | 2.4 g | 1 day | — |
| Postprandial Vascular Effects of a High Potassium Meal in Patients with Treated Hypertension 2024 · Low-potassium meal · Adults aged 18–80 with controlled, treated hypertension | 543 mg | 1 day | — |
| A randomized, controlled trial of oral sulfate solution versus polyethylene glycol for bowel preparation for colonoscopy 2025 · Group A (OSS) · Men and women aged 18–70 years undergoing screening, surveillance, or diagnostic colonoscopy | 3.13 g | 1 day | 324 |
| Effects of magnesium and potassium supplementation on insomnia and sleep hormones in patients with diabetes mellitus 2024 · T4: Magnesium + potassium · Men and women aged 19–65 with diabetes and insomnia | 500 mg | 60 days | 73 |
| Effect of creatine phosphate supplementation on anaerobic working capacity and body weight after two and six days of loading in men and women 2005 · CrP · Men and women; ages and health condition not reported | 4 g | 6 days | — |
| Infant neurocognitive development is independent of the use of iodised salt or iodine supplements given during pregnancy 2013 · 200 μg KI/d group · Pregnant women in their first trimester | 200 mcg | — | — |
| Infant neurocognitive development is independent of the use of iodised salt or iodine supplements given during pregnancy 2013 · 300 μg KI/d group · Pregnant women in their first trimester | 300 mcg | — | — |
| Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators 1997 · active therapy · Patients with frequent ventricular arrhythmias (>720 ventricular premature beats per 24 hours); age and sex not specified | 12 mmol | 3 weeks | — |
| The effect of potassium supplementation in persons with a high-normal blood pressure. Results from phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group 1995 · active treatment group · men and women with high-normal blood pressure and initial average diastolic blood pressure of 80–89 mm Hg | 60 mmol | 26 weeks | 178 |
| Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension 1998 · K supplementation period · Adults aged 36–77 with essential hypertension | 64 mmol | 4 weeks | 55 |
| Potassium supplementation versus bendrofluazide in mildly to moderately hypertensive Kenyans 1991 · Group A (potassium supplementation) · Black adults with confirmed but untreated hypertension | 64 mmol | 28 weeks | 42 |
| The effect of low-dose potassium supplementation on blood pressure in apparently healthy volunteers 2003 · 24 mmol slow-release KCl/d · Apparently healthy volunteers | 24 mmol | 6 weeks | 30 |
| Short-Term RCT of Increased Dietary Potassium from Potato or Potassium Gluconate: Effect on Blood Pressure, Microcirculation, and Potassium and Sodium Retention in Pre-Hypertensive-to-Hypertensive Adults 2021 · K gluconate intervention · Men and women aged 21 years and older with pre-hypertensive-to-hypertensive blood pressure who were otherwise apparently healthy | 26 mmol | 16 days | 30 |
| Randomized Trial on the Effects of Dietary Potassium on Blood Pressure and Serum Potassium Levels in Adults with Chronic Kidney Disease 2021 · higher-K diet · Adults older than 18 with stage 3 chronic kidney disease and systolic blood pressure 120–159 mmHg | 100 mmol | 4 weeks | 29 |
| Randomized Trial on the Effects of Dietary Potassium on Blood Pressure and Serum Potassium Levels in Adults with Chronic Kidney Disease 2021 · lower-K diet · Adults older than 18 with stage 3 chronic kidney disease and systolic blood pressure 120–159 mmHg | 40 mmol | 4 weeks | 29 |
| The effect of a dietary supplement of potassium chloride or potassium citrate on blood pressure in predominantly normotensive volunteers 2008 · potassium citrate (K-cit) · Predominantly young, healthy, normotensive volunteers; age and sex not specified | 30 mmol | 6 weeks | 28 |
| [Potassium citrate versus potassium chloride in essential hypertension. Effects on hemodynamic, hormonal and metabolic parameters] 1995 · potassium citrate · Adults aged 24–70 years with essential hypertension | 120 mmol | 8 weeks | 25 |
| [Potassium citrate versus potassium chloride in essential hypertension. Effects on hemodynamic, hormonal and metabolic parameters] 1995 · potassium chloride · Adults aged 24–70 years with essential hypertension | 120 mmol | 8 weeks | 25 |
| Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension 1992 · potassium chloride · Patients aged 60 years or older with hypertension | 120 mmol | 4 days | 22 |
| Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients 1992 · potassium supplements · Elderly untreated hypertensive patients, mean age 75 years (range 66–79), with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg | 60 mmol | 4 weeks | 18 |
| Effect of short-term supplementation of potassium chloride and potassium citrate on blood pressure in hypertensives 2005 · potassium chloride · 14 hypertensive individuals; age and sex not specified | 96 mmol | 7 days | 14 |
| Effect of short-term supplementation of potassium chloride and potassium citrate on blood pressure in hypertensives 2005 · potassium citrate · 14 hypertensive individuals; age and sex not specified | 96 mmol | 7 days | 14 |
| Potassium depletion exacerbates essential hypertension 1991 · Low-potassium diet · 12 patients with essential hypertension; age and sex not specified | 16 mmol | 10 days | 12 |
| Potassium depletion exacerbates essential hypertension 1991 · High-potassium diet · 12 patients with essential hypertension; age and sex not specified | 96 mmol | 10 days | 12 |
| Potassium supplementation in the treatment of idiopathic postural hypotension 1990 · potassium · Elderly patients with symptomatic idiopathic postural hypotension | 60 mmol | — | 10 |
| Long-term potassium supplementation lowers blood pressure in elderly hypertensive subjects 1997 · 60 mmol/day potassium supplement phase · Elderly subjects with hypertension | 60 mmol | 4 weeks | 8 |
| Long-term potassium supplementation lowers blood pressure in elderly hypertensive subjects 1997 · 48 mmol daily potassium supplementation phase · Elderly subjects with hypertension | 48 mmol | 120 days | 8 |
| Effects of potassium on blood pressure in salt-sensitive and salt-resistant black adolescents 1999 · high potassium diet · Black adolescents who were salt-sensitive or salt-resistant | 80 mmol | 3 weeks | — |
| Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial 2001 · potassium supplementation group · Men and women aged 35–64 years with initial systolic blood pressure 130–159 mmHg and/or diastolic blood pressure 80–94 mmHg, living in a community in Beijing, China | 60 mmol | 12 weeks | — |
| Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study 1990 · potassium alone · Adults with mild hypertension (diastolic blood pressure less than 110 mm Hg) | 60 mmol | 32 weeks | — |
| Effects of sodium and potassium supplementation on blood pressure and arterial stiffness: a fully controlled dietary intervention study 2015 · supplemental potassium · Untreated (pre)hypertensive individuals; age and sex not specified | 3 g | 4 weeks | — |
| Effects of potassium supplementation on markers of osmoregulation and volume regulation: results of a fully controlled dietary intervention study 2016 · potassium · (Pre)hypertensive individuals; ages and sex not reported | 2.8 g | 4 weeks | — |
| Effect of potassium supplementation on blood pressure in African Americans on a low-potassium diet. A randomized, double-blind, placebo-controlled trial 1996 · potassium supplements · Healthy African Americans aged 27 to 65 years with systolic blood pressure of 100 to 159 mm Hg and diastolic blood pressure of 70 to 94 mm Hg | 80 mmol | 3 weeks | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · potassium · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 40 mmol | 16 weeks | — |
| Effects of creatine supplementation on body composition, strength, and sprint performance 1998 · Phosphagen HP (HP) · NCAA Division IA football players undergoing resistance/agility training; age and sex not stated | 1.2 g | 4 weeks | — |
| [Long term observation in effects of potassium and calcium supplementation on arterial blood pressure and sodium metabolism in adolescents with higher blood pressure] 2003 · supplementary group · Adolescents aged 18–22 with higher blood pressure | 10 mmol | 2 years | 110 |
| Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study 1990 · potassium with magnesium · Adults with mild hypertension (diastolic blood pressure less than 110 mm Hg) | 60 mmol | 32 weeks | — |
| Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake 1998 · all three minerals together · Normotensive women, mean age 39, with low habitual intake of potassium, calcium, and magnesium | 40 mmol | 16 weeks | — |
| Treatment-induced increase in total body potassium in patients at high risk of ventricular arrhythmias; a randomized POTCAST substudy 2023 · Intervention group · Adults aged 18 or older with an implantable cardioverter defibrillator and baseline plasma potassium ≤4.0 mmol/L, at high risk of malignant arrhythmias; normokalemic at baseline | 2.68 g | 26 weeks | 7 |
| Partial substitution of sodium with potassium in white bread: feasibility and bioavailability 2009 · potassium-chloride-fortified bread · Six volunteers; age, sex, and health condition not specified | 22 mmol | 11 days | 6 |
| Potassium substitution via the oral route: does its efficacy depend on the anion of the potassium salt? 1991 · potassium chloride (KCl) group · Patients with hypokalemia (serum potassium ≤3.5 mmol/L); age and sex not reported | 80 mmol | 6 days | — |
| Potassium substitution via the oral route: does its efficacy depend on the anion of the potassium salt? 1991 · potassium citrate/bicarbonate (K-cit/bic) group · Patients with hypokalemia (serum potassium ≤3.5 mmol/L); age and sex not reported | 80 mmol | 6 days | — |
| Adequacy of twice daily dosing with potassium chloride and spironolactone in thiazide treated hypertensive patients 1991 · potassium chloride · Hypertensive patients taking bendrofluazide | 64 mmol | 6 weeks | — |
| Effects of sodium intake and diet on racial differences in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH)-Sodium trial 2013 · Control diet · Adults with prehypertension or stage 1 hypertension | 1.7 g | 90 days | — |
| Effects of sodium intake and diet on racial differences in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH)-Sodium trial 2013 · DASH diet · Adults with prehypertension or stage 1 hypertension | 4.1 g | 90 days | — |
| Kaliuresis and Intracellular Uptake of Potassium with Potassium Citrate and Potassium Chloride Supplements: A Randomized Controlled Trial 2023 · potassium citrate · 18 healthy individuals | 40 mmol | 1 day | — |
| Kaliuresis and Intracellular Uptake of Potassium with Potassium Citrate and Potassium Chloride Supplements: A Randomized Controlled Trial 2023 · potassium chloride · 18 healthy individuals | 40 mmol | 1 day | — |
| Comparative Efficacy of Magnesium and Potassium Towards Cholesterol and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomised Single-Blinded Controlled Clinical Trial 2024 · Group III (T3) · Adults aged 25–85 with type 2 diabetes mellitus; both sexes | 500 mg | 60 days | 74 |
| The Amelioration of Insulin Resistance in Salt Loading Subjects by Potassium Supplementation is Associated with a Reduction in Plasma IL-17A Levels 2017 · high-salt diet with potassium supplementation · Normotensive adults aged 29 to 65 years undergoing salt loading | 4.5 g | 7 days | 45 |
| The Effect of Salt Intake and Potassium Supplementation on Serum Gastrin Levels in Chinese Adults: A Randomized Trial 2017 · High-salt diet + potassium supplementation · Chinese adults from a rural community in northern China; normotensive or mildly hypertensive | 60 mmol | 7 days | 44 |
| Effect of sodium and potassium supplementation on vascular and endothelial function: a randomized controlled trial 2015 · high-potassium, high-sodium meal (HKHN) · Healthy, normotensive adults; mean age 37 ± 15 years; 21 women and 18 men | 38 mmol | 1 day | 39 |
| Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study 2020 · potassium supplementation · Adults aged 40–80 with untreated prehypertension (fasting office systolic blood pressure 130–159 mm Hg); predominantly male | 2.8 g | 4 weeks | 36 |
| Does potassium citrate administration change the type and composition of encrusted material on Double-J stent compared to primary stone? 2021 · intervention group (citrate) · Adults who underwent transurethral lithotripsy and Double-J stent insertion for ureteral stones | 30 mmol | 50 days | 33 |
| Effects of monitoring dietary biomarkers and providing vegetable juice on metabolic syndrome components in adults with an overweight or obese body mass index in Ulaanbaatar: a randomized controlled trial 2025 · monitoring + vegetable juice group · Healthy Mongolian adults aged 20 years or older with BMI ≥25 kg/m²; men and women | 700 mg | 8 weeks | 32 |
| Short-Term Supplemental Dietary Potassium from Potato and Potassium Gluconate: Effect on Calcium Retention and Urinary pH in Pre-Hypertensive-to-Hypertensive Adults 2021 · K-gluconate supplement · Men and women aged 21 years and older with systolic blood pressure >120 mmHg | 1 g | 16 days | 30 |
| Effect of Increased Potassium Intake on Adrenal Cortical and Cardiovascular Responses to Angiotensin II: A Randomized Crossover Study 2021 · Potassium treatment · Men aged 20–55 years with normotension and no stated diagnosed disease | 90 mmol | 4 weeks | 25 |
| Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans 2012 · potassium supplementation · Healthy participants; age and sex not specified | 100 mmol | 4 weeks | 21 |
| Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion 2000 · Potassium bicarbonate alone · Women aged 50 years or older | 60 mmol | 2 weeks | 19 |
| Acute effects of calcium carbonate, calcium citrate and potassium citrate on markers of calcium and bone metabolism in young women 2009 · potassium citrate · Healthy women aged 22–30 years | 2.25 g | 1 day | 12 |
| Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene 1990 · bendrofluazide plus potassium · 12 normal subjects; age and sex not reported | 24 mmol | 5 days | 12 |
| Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans 2002 · hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl/d) · nine male hypertensive subjects | 20 mmol | 2 weeks | 9 |
| Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: results of a randomized controlled trial 2012 · KHCO3 supplementation during high NaCl intake · Healthy adult men | 90 mmol | 10 days | 8 |
| Glucocorticoid activity and metabolism with NaCl-induced low-grade metabolic acidosis and oral alkalization: results of two randomized controlled trials 2016 · High-NaCl diet supplemented with KHCO3 · Eight young, healthy, normal-weight men | 90 mmol | 10 days | 8 |
| Potassium supplementation ameliorates mineralocorticoid-induced sodium retention 1993 · KCl · Eight healthy subjects; age range and sex not reported | 80 mmol | 10 days | 8 |
| Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion 2000 · HCTZ plus potassium chloride · Healthy men and women aged 50 years or older | 60 mmol | 2 weeks | — |
| Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion 2000 · HCTZ plus potassium bicarbonate · Healthy men and women aged 50 years or older | 60 mmol | 2 weeks | — |
| Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet 2002 · high-salt diet plus potassium citrate · Postmenopausal women | 90 mmol | 4 weeks | — |
| Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women 2005 · potassium citrate · postmenopausal women | 4.3 g | 2 weeks | — |
| Potassium bicarbonate attenuates the urinary nitrogen excretion that accompanies an increase in dietary protein and may promote calcium absorption 2009 · KHCO3 · Healthy adults aged 54–82 years | 90 mmol | 41 days | — |
| Pharmacokinetic Profile of Incremental Oral Doses of Dietary Nitrate in Young and Older Adults: A Crossover Randomized Clinical Trial 2022 · 200 mL KNO3 solution · Healthy, nonsmoking, nonvegetarian adults aged 18–35 and 60–75 years, without comorbidities | 1 g | 1 day | 24 |
| Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension 2006 · magnesium potassium supplementation · Patients with essential hypertension; age and sex not reported | 217 mg | 4 weeks | 35 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 60 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 60 mmol | 26 weeks | 17 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 90 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 90 mmol | 26 weeks | 17 |
| Electrocardiographic changes induced by inhaled salbutamol after treatment with bendrofluazide: effects of replacement therapy with potassium, magnesium and triamterene 1990 · bendrofluazide plus potassium plus magnesium · 12 normal subjects; age and sex not reported | 24 mmol | 5 days | 12 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period I low dose (A) · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 102 mg/kg | 5 days | 4 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period I intermediate dose (B) · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 198 mg/kg | 5 days | 4 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period I high dose (C) · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 300 mg/kg | 5 days | 4 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period II regimen X · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 249 mg/kg | 5 days | 4 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period II regimen Y · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 249 mg/kg | 5 days | 4 |
| Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults 2020 · Period II regimen Z · Healthy adults aged 18–55 years, male or female, without major medical history or chronic treatment | 198 mg/kg | 5 days | 4 |
| Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women 2005 · combined treatment · postmenopausal women | 4.3 g | 2 weeks | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium bicarbonate group · Men and women aged 50 and older; described as healthy older adults | 67.5 mmol | 90 days | — |
| Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women 2009 · potassium chloride group · Men and women aged 50 and older; described as healthy older adults | 67.5 mmol | 90 days | — |
| Dietary intervention with a specific micronutrient combination for the treatment of patients with cardiac arrhythmias: the impact on insulin resistance and left ventricular function 2018 · verum group · Adults aged 18–75 with cardiac arrhythmias (ventricular or supraventricular premature beats or supraventricular tachycardia); patients with cardiovascular disorders, often including hypertension or coronary artery disease | 469 mg | 6 weeks | 29 |
| Randomized Trial to Assess the Safety and Tolerability of Daily Intake of an Allulose Amino Acid-Based Hydration Beverage in Men and Women 2024 · Group 1 (one stick of product) · Healthy men and women aged 18–50 years with BMI 20–29.9 kg/m² | 380 mg | 4 weeks | 10 |
| Randomized Trial to Assess the Safety and Tolerability of Daily Intake of an Allulose Amino Acid-Based Hydration Beverage in Men and Women 2024 · Group 2 (two sticks of product) · Healthy men and women aged 18–50 years with BMI 20–29.9 kg/m² | 760 mg | 4 weeks | 10 |
| Randomized Trial to Assess the Safety and Tolerability of Daily Intake of an Allulose Amino Acid-Based Hydration Beverage in Men and Women 2024 · Group 3 (three sticks of product) · Healthy men and women aged 18–50 years with BMI 20–29.9 kg/m² | 1.14 g | 4 weeks | 10 |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 30 mmol/d · Postmenopausal women | 30 mmol | 3 years | — |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 60 mmol/d · Postmenopausal women | 60 mmol | 3 years | — |
| Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women 2005 · KBC 90 mmol/d · Postmenopausal women | 90 mmol | 3 years | — |